Last updated: 18 July 2019 at 3:48pm EST

Thomas J. Farrell Net Worth




The estimated Net Worth of Thomas J. Farrell is at least $134 Thousand dollars as of 1 October 2015. Thomas Farrell owns over 2,500 units of Bellicum Pharmaceuticals Inc stock worth over $4,774 and over the last 10 years Thomas sold BLCM stock worth over $129,000.

Thomas Farrell BLCM stock SEC Form 4 insiders trading

Thomas has made over 3 trades of the Bellicum Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Thomas sold 2,500 units of BLCM stock worth $36,450 on 1 October 2015.

The largest trade Thomas's ever made was selling 2,500 units of Bellicum Pharmaceuticals Inc stock on 1 October 2015 worth over $36,450. On average, Thomas trades about 1,071 units every 8 days since 2014. As of 1 October 2015 Thomas still owns at least 63,862 units of Bellicum Pharmaceuticals Inc stock.

You can see the complete history of Thomas Farrell stock trades at the bottom of the page.



What's Thomas Farrell's mailing address?

Thomas's mailing address filed with the SEC is C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON, TX, 77030.

Insiders trading at Bellicum Pharmaceuticals Inc

Over the last 10 years, insiders at Bellicum Pharmaceuticals Inc have traded over $18,000,835 worth of Bellicum Pharmaceuticals Inc stock and bought 249,666 units worth $2,145,232 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli..., and Jon P Stonehouse. On average, Bellicum Pharmaceuticals Inc executives and independent directors trade stock every 32 days with the average trade being worth of $2,494. The most recent stock trade was executed by James M Daly on 3 January 2023, trading 60,414 units of BLCM stock currently worth $4,516.



What does Bellicum Pharmaceuticals Inc do?

bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.



What does Bellicum Pharmaceuticals Inc's logo look like?

Bellicum Pharmaceuticals Inc logo

Complete history of Thomas Farrell stock trades at Bellicum Pharmaceuticals Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
1 Oct 2015 Thomas J. Farrell
President and CEO
Sale 2,500 $14.58 $36,450
1 Oct 2015
63,862
1 Sep 2015 Thomas J. Farrell
President and CEO
Sale 2,500 $16.78 $41,950
1 Sep 2015
66,362
3 Aug 2015 Thomas J. Farrell
President and CEO
Sale 2,500 $20.24 $50,600
3 Aug 2015
68,862


Bellicum Pharmaceuticals Inc executives and stock owners

Bellicum Pharmaceuticals Inc executives and other stock owners filed with the SEC include: